Medicofarma Biotech SA
WSE:MDB
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.377
1.225
|
Price Target |
|
We'll email you a reminder when the closing price reaches PLN.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Medicofarma Biotech SA
Additional Paid In Capital
Medicofarma Biotech SA
Additional Paid In Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
M
|
Medicofarma Biotech SA
WSE:MDB
|
Additional Paid In Capital
zł8.9m
|
CAGR 3-Years
177%
|
CAGR 5-Years
84%
|
CAGR 10-Years
N/A
|
|
I
|
Inno-Gene SA
WSE:IGN
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
R
|
Ryvu Therapeutics SA
WSE:RVU
|
Additional Paid In Capital
zł519.7m
|
CAGR 3-Years
23%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
S
|
Selvita SA
WSE:SLV
|
Additional Paid In Capital
zł109.4m
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Medicofarma Biotech SA
Glance View
Medicofarma Biotech SA is a biotechnology company, which focuses on the innovative medicine, medicinal products, and biotechnology products. The company is headquartered in Warsaw, Woj. Mazowieckie. The company went IPO on 2008-11-27. The company is engaged in works on drugs, medical devices and biotechnological products. It's research and development works are carried out in laboratories in Lublin and Poznan.
See Also
What is Medicofarma Biotech SA's Additional Paid In Capital?
Additional Paid In Capital
8.9m
PLN
Based on the financial report for Dec 31, 2023, Medicofarma Biotech SA's Additional Paid In Capital amounts to 8.9m PLN.
What is Medicofarma Biotech SA's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
84%
Over the last year, the Additional Paid In Capital growth was 0%. The average annual Additional Paid In Capital growth rates for Medicofarma Biotech SA have been 177% over the past three years , 84% over the past five years .